These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17407795)

  • 41. Treating heart failure with sildenafil.
    Blum A
    Congest Heart Fail; 2009; 15(4):181-5. PubMed ID: 19627292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
    Sabri MR; Beheshtian E
    Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sildenafil (Revatio) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2005 Aug 15-29; 47(1215-1216):65-7. PubMed ID: 16103865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Izbicki G; Rosengarten D; Picard E
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
    [No Abstract]   [Full Text] [Related]  

  • 45. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Kuschner WG
    N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528810
    [No Abstract]   [Full Text] [Related]  

  • 46. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of phosphodiesterase-5 inhibitors by college students.
    Freitas VM; Menezes FG; Antonialli MM; Nascimento JW
    Rev Saude Publica; 2008 Oct; 42(5):965-7. PubMed ID: 18797570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.
    Xu XQ; Jing ZC; Zhang JH; Wu Y; Wang Y; Jiang X; Wang ZX; Sun YG; Pu JL; Yang YJ
    Hypertens Res; 2009 Oct; 32(10):911-5. PubMed ID: 19644505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
    Agrawal A; Tutuian R; Hila A; Castell DO
    Dig Dis Sci; 2005 Nov; 50(11):2059-62. PubMed ID: 16240215
    [No Abstract]   [Full Text] [Related]  

  • 50. [Primary arterial pulmonary hypertension and sildenafil: a case report from Dakar].
    Bouldouyre M; Dia D; Ba FK; Diop IB; Debonne JM
    Dakar Med; 2006; 51(2):78-80. PubMed ID: 17632981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphodiesterase inhibitors for pulmonary hypertension.
    Bergot E; Magnier R; Zalcman G
    N Engl J Med; 2010 Feb; 362(6):559; author reply 560. PubMed ID: 20147727
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
    Bharani A; Patel A; Saraf J; Jain A; Mehrotra S; Lunia B
    Indian Heart J; 2007; 59(4):323-8. PubMed ID: 19126937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
    Madden BP; Sheth A; Wilde M; Ong YE
    Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Viagra -- patients stand by their treatment].
    Praxis (Bern 1994); 2006 Nov; 95(47):1835-6. PubMed ID: 17168079
    [No Abstract]   [Full Text] [Related]  

  • 55. Sildenafil in older patients with secondary pulmonary hypertension.
    Minotti GC; Corsonello A; Incalzi RA
    J Am Geriatr Soc; 2007 Oct; 55(10):1681-2. PubMed ID: 17908072
    [No Abstract]   [Full Text] [Related]  

  • 56. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
    Sawamura F; Kato M; Fujita K; Nakazawa T; Beardsworth A
    J Pharmacol Sci; 2009 Nov; 111(3):235-43. PubMed ID: 19881228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sildenafil administration to a patient with refractory persistent pulmonary hypertension of the newborn.
    Latini G; Rosati E; De Felice C; Del Vecchio A
    J Matern Fetal Neonatal Med; 2008 Sep; 21(9):671-3. PubMed ID: 18828061
    [No Abstract]   [Full Text] [Related]  

  • 58. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
    Shlobin OA; Brown AW; Weir N; Ahmad S; Lemma M; Nathan SD
    Lung; 2012 Oct; 190(5):573-8. PubMed ID: 22797830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative administration of PDE-5 Inhibitors.
    Edwards AF; Roy RC
    J Clin Anesth; 2009 Mar; 21(2):149; author reply 149-50. PubMed ID: 19329023
    [No Abstract]   [Full Text] [Related]  

  • 60. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.